We actively communicate on our business, services and technical capabilities. Use the resources on this page to browse through recent news, to subscribe to our news services or to meet us at one of our forthcoming events.
Lifecore and PolyPeptide Announce Collaboration Intended to Offer End-to-End Peptide Manufacturing Solution for U.S. Market
28 Oct 2025 - Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore”), a fully integrated contract development and manufacturing organization (“CDMO”), and PolyPeptide Laboratories, Inc. (“PolyPeptide”), a global leader in peptide contract […]
Read moreCapacity expansion underway at our Ambernath facility
24 Oct 2025 - We recently announced an investment at our Ambernath facility in India—transforming it into a larger, more diverse site. This expansion is part of PolyPeptide’s strategic growth, […]
Read moreCapacity expansion for major Pharma’s hormonal disorders and women’s health portfolio
29 Sep 2025 - We recently announced a capacity expansion at our Braine-l’Alleud site in Belgium, strategically backed by customer financing. This investment underscores our commitment to capturing growth in […]
Read morePolyPeptide Group achieves significant milestone in Malmö expansion project
22 Sep 2025 - Baar, 22 September 2025 – PolyPeptide Group AG (SIX: PPGN), a specialized, global CDMO for peptide-based active pharmaceutical ingredients, today announced the successful delivery and installation […]
Read moreAlzinova testimonial: Alzheimer’s peptide vaccine with PolyPeptide
1 Sep 2025 - September is International Alzheimer’s Month, a reminder of the urgent need to advance research and treatment options for patients and families affected worldwide. It is an […]
Read moreBackbone Protecting Groups for Enhanced Peptide and Protein Synthesis
13 Aug 2025 - This review provides a comprehensive account of the use of backbone N-protecting groups in peptide synthesis. It includes detailed synthetic methods relating to their introduction and removal […]
Read morePolyPeptide delivers +24% growth in H1 2025, successful ramp-up at its Belgian site, 2025 full-year guidance revised towards the upper end of the range
12 Aug 2025 - Baar, 12 August 2025 – PolyPeptide Group AG (SIX: PPGN), a specialized global CDMO for peptide-based active pharmaceutical ingredients, today announced its results for H1 2025, […]
Read morePolyPeptide announces expansion of existing credit facilities
23 May 2025 - Baar, 23 May 2025 – PolyPeptide Group AG (SIX: PPGN), a specialized, global CDMO for peptide-based active pharmaceutical ingredients, today announced that it has secured additional […]
Read moreAlzinova Advances ALZ-101 Development with Drug Substance Release, Paving the Way for Phase 2 Clinical Trial
24 Apr 2025 - Sweden, 24 April 2025 – Alzinova AB (publ) (ticker: ALZ) is pleased to announce the release of the drug substance for its upcoming Phase 2 clinical […]
Read more